Loading clinical trials...

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

A Phase II, Open-Label Safety and Tolerability Study of an Renal Autologous Cell Therapy (REACT) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)

NCT03270956•Prokidney

View on ClinicalTrials.gov

Summary

The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).

Detailed Description

All subjects enrolled will receive REACT. Subjects will receive their first REACT injection as soon as the REACT product is manufactured and shipped to the clinical site. After 6 months (+4 weeks), a second injection will be given, as appropriate. Each subject's baseline rate of renal decline, based on adequate historical clinical data obtained 24 months prior to screening visit, will serve as a comparator for monitoring the rate of progression of renal insufficiency over time.

Eligibility

Age

30 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. The subject is male or female, 30 to 65 years of age on the date of informed consent.
•2. The subject has an established diagnosis of T2DM.
•3. The subject has an established diagnosis of diabetic nephropathy as the underlying cause of renal disease.
•4. The subject has an established diagnosis of CKD not requiring renal dialysis, defined as having an eGFR between 14 and 20 mL/min/1.73m² inclusive at the Screening Visit and prior to REACT injection.
•5. The subject has blood pressure less than 150/90 at the Screening Visit, prior to renal biopsy, and prior to REACT injection(s). Note BP should not be significantly below the previously recorded stable pressure.
•6. A minimum of 3 measurements of eGFR or sCr should be obtained at least 3 months apart prior to the Screening Visit or within the previous 24 months to define the rate of progression of CKD. The subject should have adequate, historical clinical data to provide a reasonable estimate of the rate of progression of CKD. The Medical Monitor may be consulted to ensure there is sufficient data.

Exclusion Criteria

•1. The subject has a history of type 1 diabetes mellitus.
•2. The subject has a history of renal transplantation.
•3. The subject has a serum HbA1c level greater than 10% at the Screening Visit.
•4. The subject has uncontrolled diabetes (defined as metabolically unstable by the Investigator).
•5. The subject has hemoglobin levels less than 9 g/dL prior to each REACT injection.

Locations (4)

University of Arizona [WITHDRAWN]

Tucson, Arizona, United States

Boise Kidney & Hypertension Institute

Boise, Idaho, United States

University of North Carolina- Chapel Hill

Chapel Hill, North Carolina, United States

Vanderbilt University [WITHDRAWN]

Nashville, Tennessee, United States

Key Dates

Start Date

April 25, 2018

Primary Completion Date

November 17, 2022

Completion Date

November 17, 2022

Last Updated

March 24, 2025

Enrollment

ACTUAL participants

Conditions

Type 2 Diabetes MellitusChronic Kidney Disease

Interventions

Renal Autologous Cell Therapy (REACT)

BIOLOGICAL

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390

Atherosclerosis Cardiovascular DiseaseChronic Kidney Disease

View study

RECRUITINGNA

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

Inclusion Criteria

Exclusion Criteria

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Feasibility of a Tailored Online Self-compassion Intervention

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Achieving Routine Intervention and Screening for Emotional Health

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD